According to a new report, published by KBV research, The Global Diabetes Care Devices Market size is expected to reach $29.3 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.
The Blood Glucose Monitoring Devices market is showcasing a CAGR of 6.1% during (2022 - 2028). Because of features like mobility and accuracy, blood glucose meters are gradually becoming more popular. Small blood glucose meters are being introduced by market participants that are also working on creating these devices. In addition, during the forecast years, the launch of these tiny, discreet, and easy-to-use blood glucose meters is likely to increase segment growth.
The North America market dominated the Global Diabetes Care Devices Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $11.3 billion by 2028. The Europe market is estimated to witness a CAGR of 5.3% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 6.1% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/diabetes-care-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, Sanofi S.A., Zealand Pharma A/S, B. Braun Melsungen AG, Bayer AG, Abbott Laboratories, Ypsomed AG, Arkray, Inc.
By Product
By Geography
Companies Profiled
Unique Offerings 
